This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oil and Drug Splits: Deals to Watch

Stocks in this article: ABT WMB WPZ SUG ETP BCS C JPM

NEW YORK ( TheStreet) - Abbott Laboratories (ABT) said Wednesday it will split itself into separate into two publicly traded companies; one focusing on medical products and the other on pharmaceuticals research and development. Abbott said that its medical products division will continue under its heritage name founded in 1888, and the research division will form a new publicly traded stock, not yet named. To make the split, current Abbott shareholders will be given stock in the new publicly traded company when it files an initial public offering.

Shares rose over 4.5% in early trading to $54.85. The company's stock has risen more than 10% this year outperforming the S&P 500. It also increased its quarterly dividend from 44 cents a share to 48 cents in April. In its announcement of the split, Abbot said that the dividend of the combined companies will match current levels and that the decision to spin its drug R&D division won't affect earnings-per-share.

"Today's news is a significant event for Abbott, and reflects another dynamic change in our company's 123-year history, strengthening our outlook for strong and sustainable growth and shareholder returns," said Miles D. White, chief executive of Abbott in a statement announcing the deal.

Abbott expects the deal to close at the end of 2012 and said in its statement that the board of directors has not yet approved the split, which is also pending approval from the IRS for its tax free nature. Abbott also expects one-time charges while the split is completed, to be quantified later. It did not yet announce any financial advisors.

In its most recent quarter ended in September, Abbott announced that earnings and operating income had fallen by more than 50% from levels in the period a year earlier. The company's net income was $4.6 billion in 2010, below $5.7 billion earned a year earlier, but revenue grew to a record $35.1 billion. In 2010, Abbott bought European pharmaceutical and vaccines giant Solvay for roughly $6.6 billion in a push to expand its reach into Eastern Europe and Asia.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs